RS54702B1 - PYRAZOLOCHINOLINE DERIVATIVES AS PDE9 INHIBITORS - Google Patents

PYRAZOLOCHINOLINE DERIVATIVES AS PDE9 INHIBITORS

Info

Publication number
RS54702B1
RS54702B1 RS20160232A RSP20160232A RS54702B1 RS 54702 B1 RS54702 B1 RS 54702B1 RS 20160232 A RS20160232 A RS 20160232A RS P20160232 A RSP20160232 A RS P20160232A RS 54702 B1 RS54702 B1 RS 54702B1
Authority
RS
Serbia
Prior art keywords
group
atom
halogen
atoms
hydrogen atom
Prior art date
Application number
RS20160232A
Other languages
English (en)
Serbian (sr)
Inventor
Yoshihiko Norimine
Kunitoshi Takeda
Koji Hagiwara
Yuichi Suzuki
Yuki Ishihara
Nobuaki Sato
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of RS54702B1 publication Critical patent/RS54702B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20160232A 2011-10-07 2012-10-04 PYRAZOLOCHINOLINE DERIVATIVES AS PDE9 INHIBITORS RS54702B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161544860P 2011-10-07 2011-10-07
US201161550623P 2011-10-24 2011-10-24
US201161558110P 2011-11-10 2011-11-10
US201161580903P 2011-12-28 2011-12-28
PCT/JP2012/075748 WO2013051639A1 (ja) 2011-10-07 2012-10-04 ピラゾロキノリン誘導体

Publications (1)

Publication Number Publication Date
RS54702B1 true RS54702B1 (en) 2016-08-31

Family

ID=48043792

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160232A RS54702B1 (en) 2011-10-07 2012-10-04 PYRAZOLOCHINOLINE DERIVATIVES AS PDE9 INHIBITORS

Country Status (33)

Country Link
US (2) US8563565B2 (de)
EP (1) EP2769980B1 (de)
JP (1) JP5546693B2 (de)
KR (1) KR101943680B1 (de)
CN (1) CN103930423B (de)
AR (1) AR088235A1 (de)
AU (1) AU2012319549B2 (de)
BR (1) BR112014007912B1 (de)
CA (1) CA2861795C (de)
CL (1) CL2014000821A1 (de)
CO (1) CO6910200A2 (de)
CY (1) CY1117427T1 (de)
DK (1) DK2769980T3 (de)
ES (1) ES2568015T3 (de)
HK (1) HK1199018A1 (de)
HR (1) HRP20160273T1 (de)
HU (1) HUE028555T2 (de)
IL (1) IL231650A (de)
IN (1) IN2014CN02463A (de)
JO (1) JO3116B1 (de)
ME (1) ME02394B (de)
MX (1) MX358149B (de)
MY (1) MY167698A (de)
PE (1) PE20141557A1 (de)
PL (1) PL2769980T3 (de)
RS (1) RS54702B1 (de)
RU (1) RU2605096C2 (de)
SG (1) SG11201400717QA (de)
SI (1) SI2769980T1 (de)
SM (1) SMT201600108B (de)
TW (1) TWI562993B (de)
WO (1) WO2013051639A1 (de)
ZA (1) ZA201402439B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2886885C (en) 2011-10-10 2019-07-16 H. Lundbeck A/S Pde9i with imidazo pyrazinone backbone
EP2982674B1 (de) * 2013-04-05 2017-10-25 Eisai R&D Management Co., Ltd. Pyridinylpyrazolochinolinverbindung
CA2907971C (en) 2013-04-05 2020-12-29 Eisai R&D Management Co., Ltd. Salt of pyrazoloquinoline derivative, and crystal thereof
GB201406486D0 (en) 2014-04-10 2014-05-28 Redx Pharma Ltd Antibacterial compounds
WO2016021192A1 (en) * 2014-08-08 2016-02-11 Eisai R&D Management Co., Ltd. Process for production of (s)-(tetrahydrofuran-3-yl)hydrazine
EP4335497A3 (de) 2015-07-07 2024-05-01 H. Lundbeck A/S Pde9-inhibitor mit imidazopyrazinon-rückgrat zur behandlung von peripheren erkrankungen
WO2017046606A1 (en) * 2015-09-18 2017-03-23 Redx Pharma Plc Antibacterial compounds
CN107056690A (zh) * 2017-03-22 2017-08-18 上海康鹏科技有限公司 一种6‑溴吡啶‑3‑甲醛的制备方法
CA3059539A1 (en) * 2017-06-01 2018-12-06 Eisai R&D Management Co., Ltd. Pharmaceutical composition comprising pde9 inhibitor
BR112019023595A2 (pt) * 2017-06-01 2020-05-26 Eisai R&D Management Co., Ltd. Agente terapêutico da demência combinando derivados de pirazoloquinolina e memantina
TWI784006B (zh) * 2017-06-01 2022-11-21 日商衛材R&D企管股份有限公司 含有吡唑并喹啉衍生物之路易氏體症治療劑
KR102627787B1 (ko) * 2017-06-01 2024-01-23 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체와 도네페질을 병용한 치매 치료제
CN111630042A (zh) * 2018-01-23 2020-09-04 巴斯夫欧洲公司 吡啶衍生物的卤化
KR20210053948A (ko) * 2018-08-31 2021-05-12 이마라 인크. 겸상 세포 질환의 치료를 위한 pde9 억제제
AU2020268409A1 (en) * 2019-05-09 2021-11-25 The Feinstein Institutes For Medical Research Compounds for use in synthesis of peptidomimetics
US11883461B2 (en) 2019-05-09 2024-01-30 The Feinstein Institutes For Medical Research HMGB1 antagonist treatment of severe sepsis
US11471507B2 (en) 2019-05-09 2022-10-18 The Feinstein Institutes For Medical Research HMGB1 antagonist
EP3966201A4 (de) 2019-05-09 2023-01-18 The Feinstein Institutes for Medical Research Thiosemicarbazate und ihre verwendungen
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
CR20220584A (es) * 2020-04-16 2023-02-15 Incyte Corp Inhibidores de kras tricíclicos fusionados
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
CA3188782A1 (en) 2020-06-30 2022-01-06 Bayer Aktiengesellschaft Substituted heteroaryloxypyridines, the salts thereof and their use as herbicidal agents
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
US11939328B2 (en) 2021-10-14 2024-03-26 Incyte Corporation Quinoline compounds as inhibitors of KRAS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2426734C2 (ru) * 2003-10-03 2011-08-20 Зм Инновейтив Пропертиз Компани Пиразолопиридины и их аналоги
WO2005118583A1 (en) * 2004-05-28 2005-12-15 Millennium Pharmaceuticals, Inc. 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors
US8193356B2 (en) * 2005-09-15 2012-06-05 Aska Pharmaceutical Co., Ltd. Heterocycle compound, and production process and application thereof
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
ES2599054T3 (es) * 2006-12-13 2017-01-31 Aska Pharmaceutical Co., Ltd. Derivados de quinoxalina
ATE540954T1 (de) 2007-05-11 2012-01-15 Pfizer Aminoheterocyclische verbindungen
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
BRPI1009287A2 (pt) * 2009-03-05 2019-09-24 Astellas Pharma Inc composto de quinoxalina
MY156377A (en) 2009-03-31 2016-02-15 Boehringer Ingelheim Int 1-heterocycl-1, 5-dihydro-pyrazolo [3 , 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US8880976B2 (en) 2009-09-25 2014-11-04 Stmicroelectronics, Inc. Method and apparatus for encoding LBA information into the parity of a LDPC system
EA023493B1 (ru) 2010-09-07 2016-06-30 Астеллас Фарма Инк. Производное пиразолохинолина
JP6042060B2 (ja) * 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用

Also Published As

Publication number Publication date
ME02394B (de) 2016-09-20
JO3116B1 (ar) 2017-09-20
TWI562993B (en) 2016-12-21
SG11201400717QA (en) 2014-06-27
WO2013051639A1 (ja) 2013-04-11
IN2014CN02463A (de) 2015-06-19
HUE028555T2 (en) 2016-12-28
EP2769980A1 (de) 2014-08-27
ES2568015T3 (es) 2016-04-27
EP2769980B1 (de) 2016-02-03
JP5546693B2 (ja) 2014-07-09
KR20140082684A (ko) 2014-07-02
SI2769980T1 (sl) 2016-08-31
AR088235A1 (es) 2014-05-21
IL231650A0 (en) 2014-05-28
PL2769980T3 (pl) 2016-07-29
CN103930423A (zh) 2014-07-16
CL2014000821A1 (es) 2014-07-25
US8563565B2 (en) 2013-10-22
EP2769980A4 (de) 2015-02-25
CO6910200A2 (es) 2014-03-31
BR112014007912B1 (pt) 2022-06-07
BR112014007912A2 (pt) 2017-04-04
KR101943680B1 (ko) 2019-01-29
US20130296352A1 (en) 2013-11-07
PE20141557A1 (es) 2014-11-15
AU2012319549A1 (en) 2014-04-24
ZA201402439B (en) 2015-03-25
MX358149B (es) 2018-08-07
SMT201600108B (it) 2016-04-29
CN103930423B (zh) 2015-09-16
RU2014112931A (ru) 2015-11-20
US20130143907A1 (en) 2013-06-06
HRP20160273T1 (hr) 2016-04-08
MX2014003800A (es) 2014-07-28
JPWO2013051639A1 (ja) 2015-03-30
CA2861795A1 (en) 2013-04-11
TW201321379A (zh) 2013-06-01
MY167698A (en) 2018-09-21
DK2769980T3 (en) 2016-04-11
NZ622594A (en) 2015-06-26
RU2605096C2 (ru) 2016-12-20
AU2012319549B2 (en) 2016-07-28
HK1199018A1 (zh) 2015-06-19
IL231650A (en) 2016-05-31
CA2861795C (en) 2018-12-04
CY1117427T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
RS54702B1 (en) PYRAZOLOCHINOLINE DERIVATIVES AS PDE9 INHIBITORS
RS54183B1 (en) PIRAZOLE DERIVATIVES
RS54175B1 (en) BROMODOMEN INHIBITORS AND THEIR APPLICATION
RS54260B1 (en) AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
RS52261B (en) AMIDOPHENOX INDASOLS AS A USEFUL C-MET INHIBITOR
RS54048B1 (en) PARASITICIDE COMPOUNDS OF DIHYDROISOXAZOLE
MX344276B (es) Compuesto de piperidina novedoso o sal del mismo.
EA201890098A3 (ru) Производное хинолона
RS54506B1 (en) PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS
RS54708B1 (en) ARYLETINYL DERIVATIVES
RS52514B (en) DERIVATI AMINO NIKOTINSKE I IZONIKOTINSKE KISELINE KAO INHIBITORI DHODH
RS54840B1 (sr) 1-(3,3-dimetilbutil)-3-(2-fluoro-4-metil-5-(7-metil-2-(metilamino)pirido(2,3-d)pirimidin-6-il)fenil)urea kao inhibitor raf kinaze za tretman kancera
RS51949B (en) INHIBITORI KINAZE
RS52216B (en) UNITS AND METHODS FOR FXR MODULATION
EP2597088A4 (de) P2x4-rezeptor-antagonisten
RS54480B1 (en) IMIDAZOPYRIDASINE AS ACT KINASE INHIBITORS
MY165585A (en) Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
MX2009011769A (es) Derivados de piridona como inhibidores de mapk p38a.
RS54825B1 (sr) Derivati azola
RS52964B (en) 7-PIPERIDINOALKIL-3,4-DIHYDROKVINOLONE DERIVATIVE
IN2014DN07509A (de)
RS52515B (en) QUICKLY DISSOCATING DOPAMIN 2 RECEPTOR ANTAGONISTS
MX2016005993A (es) Anfifilos biscationicos y triscationicos como agentes antimicrobianos.